Pharmacokinetics of grepafloxacin after oral administration of single and repeat doses in healthy young males

Clinical Pharmacokinetics

Volumn 33, Issue SUPPL. 1, 1997, Pages 1-8

  Efthymiopoulos, C ^a   Bramer, S L ^a   Maroli, A ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GREPAFLOXACIN; QUINOLONE DERIVATIVE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BACTERICIDAL ACTIVITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG URINE LEVEL; HUMAN; HUMAN EXPERIMENT; KIDNEY CLEARANCE; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PLASMA CLEARANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFECTION; SEXUALLY TRANSMITTED DISEASE; STEADY STATE; URINARY EXCRETION;

EID: 0031453487     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-199700331-00003     Document Type: Article

References (19)

1. 1. HS Sader ME Erwin RN Jones 1992 In vitro activity of OPC-17116 compared to other broad-spectrum fluoroquinolones Eur J Clin Microbiol Infect Dis 11 4 372 81 1327789 10.1007/BF01962081 1:CAS:528:DyaK38XmtVyktLk%3D Sader HS, Erwin ME, Jones RN. In vitro activity of OPC-17116 compared to other broad-spectrum fluoroquinolones. Eur J Clin Microbiol Infect Dis 1992; 11(4): 372–81
2. 2. T Imada S Miyazaki M Nishida 1992 In vitro and in vivo antibacterial activities of a new quinolone, OPC-17116 Anti-microb Agents Chemother 36 573 9 10.1128/AAC.36.3.573 1:CAS:528:DyaK38XitVOgtLg%3D Imada T, Miyazaki S, Nishida M, et al. In vitro and in vivo antibacterial activities of a new quinolone, OPC-17116. Anti-microb Agents Chemother 1992; 36: 573–9
3. 3. H Wakebe S Mitsuhashi 1992 Comparative in vitro activities of a new quinolone, OPC-17116, possessing potent activity against gram-positive bacteria Antimicrob Agents Chemother 36 10 2185 91 1332589 10.1128/AAC.36.10.2185 1:CAS:528:DyaK38Xmt12qurg%3D Wakebe H, Mitsuhashi S. Comparative in vitro activities of a new quinolone, OPC-17116, possessing potent activity against gram-positive bacteria. Antimicrob Agents Chemother 1992; 36(10): 2185–91
4. 4. JM Zenilman T Neuman M Patton 1993 Antibacterial activities of OPC-17116, ofloxacin, and ciprofloxacin against 200 isolates of Neiserria gonorrhoeae Antimicrob Agents Chemother 36 2244 6 10.1128/AAC.37.10.2244 Zenilman JM, Neuman T, Patton M, et al. Antibacterial activities of OPC-17116, ofloxacin, and ciprofloxacin against 200 isolates of Neiserria gonorrhoeae. Antimicrob Agents Chemother 1993; 36: 2244–6
5. 5. DL Sewell AL Barry SD Allen 1966 Tentative interpretative criteria for testing susceptibility of Streptococcus pneumoniae to eight fluoroquinolones Diagn Microbiol Infect Dis 26 23 7 Sewell DL, Barry AL, Allen SD, et al. Tentative interpretative criteria for testing susceptibility of Streptococcus pneumoniae to eight fluoroquinolones. Diagn Microbiol Infect Dis 1966; 26: 23–7
6. 6. SK Spangler MR Jacobs GA Pankuch 1993 Susceptibility of 170 penicillin-susceptible and penicillin-resistant pneumococci to six oral cephalosporins, four quinolones, desacetyl-cefotaxime, RO 23-9424 and PR 67829 J Antimicrob Chemother 31 2 273 80 8463172 10.1093/jac/31.2.273 1:CAS:528:DyaK3sXisFWgsL4%3D Spangler SK, Jacobs MR, Pankuch GA, et al. Susceptibility of 170 penicillin-susceptible and penicillin-resistant pneumococci to six oral cephalosporins, four quinolones, desacetyl-cefotaxime, RO 23-9424 and PR 67829. J Antimicrob Chemother 1993; 31(2): 273–80
7. 7. HC Neu W Fang JW Gu 1992 In vitro activity of OPC-17116 Antimicrob Agents Chemother 36 1310 5 1329620 10.1128/AAC.36.6.1310 1:CAS:528:DyaK38Xks1KnsrY%3D Neu HC, Fang W, Gu JW, et al. In vitro activity of OPC-17116. Antimicrob Agents Chemother 1992; 36: 1310–5
8. 8. M Gibaldi D Perrier 1989 Pharmacokinetics 2nd Marcel Dekker New York Gibaldi M, Perrier D. Pharmacokinetics. 2nd ed. New York: Marcel Dekker, 1989
9. 9. Suri A. Report 106-96-203. Retrospective estimation of the absolute bioavailability of grepafloxacin in healthy male subjects using pooled data from two studies
10. 10. Akiyama H, Odomi M. Report 8850. Metabolism of 14C-OPC-17116 by 10 human cytochrome P450 isoforms expressed by recombinant vaccinia virus
11. 11. Report 5331. Protein binding of OPC-17116 in vitro
12. 12. K Vance-Bryan DRP Guay JC Rotschafer 1990 Clinical pharmacokinetics of ciprofloxacin Clin Pharmacokinet 19 434 61 2292168 10.2165/00003088-199019060-00003 1:CAS:528:DyaK3MXkt1WgtLc%3D Vance-Bryan K, Guay DRP, Rotschafer JC. Clinical pharmacokinetics of ciprofloxacin. Clin Pharmacokinet 1990; 19: 434–61
13. 13. KC Lamp EM Bailey MJ Rybak 1992 Ofloxacin clinical pharmacokinetics Clin Pharmacokinet 22 32 6 1559306 10.2165/00003088-199222010-00004 1:STN:280:DyaK383hslamsg%3D%3D Lamp KC, Bailey EM, Rybak MJ. Ofloxacin clinical pharmacokinetics. Clin Pharmacokinet 1992; 22: 32–6
14. 14. DN Fish AT Chow 1997 The clinical pharmacokinetics of Levofloxacin Clin Pharmacokinet 32 101 19 9068926 10.2165/00003088-199732020-00002 1:CAS:528:DyaK2sXitVWrur0%3D Fish DN, Chow AT. The clinical pharmacokinetics of Levofloxacin. Clin Pharmacokinet 1997; 32: 101–19
15. 15. KL Goa HM Bryson A Markham 1997 Sparfloxacin. A review of its antibacterial activity, pharmacokinetic properties, clinical efficacy and tolerability in lower respiratory tract infections Drugs 53 700 25 9098667 10.2165/00003495-199753040-00010 1:CAS:528:DyaK2sXisFGgurY%3D Goa KL, Bryson HM, Markham A. Sparfloxacin. A review of its antibacterial activity, pharmacokinetic properties, clinical efficacy and tolerability in lower respiratory tract infections. Drugs 1997; 53: 700–25
16. 16. R Teng SC Harris DE Nix 1995 Pharmacokinetics and safety of trovafloxacin (CP-99,219), a new quinolone antibiotic, following administration of single oral doses to healthy male volunteers J Antimicrob Chemother 36 385 94 8522468 10.1093/jac/36.2.385 1:CAS:528:DyaK2MXnvVKmtb4%3D Teng R, Harris, SC, Nix DE, et al. Pharmacokinetics and safety of trovafloxacin (CP-99,219), a new quinolone antibiotic, following administration of single oral doses to healthy male volunteers. J Antimicrob Chemother 1995; 36: 385–94
17. 17. R Teng TE Liston SC Harris 1996 Multiple dose pharmacokinetics and safety of trovafloxacin in healthy volunteers J Antimicrob Chemother 37 955 63 8737145 10.1093/jac/37.5.955 1:CAS:528:DyaK28XjvVWqsro%3D Teng R, Liston TE, Harris SC. Multiple dose pharmacokinetics and safety of trovafloxacin in healthy volunteers. J Antimicrob Chemother 1996; 37: 955–63
18. 18. J Child JM Andrews R Wise 1995 Pharmacokinetics and tissue penetration of the new fluoroquinolone grepafloxacin Antimicrob Agents Chemother 39 513 5 7726523 10.1128/AAC.39.2.513 1:CAS:528:DyaK2MXjsFCitb4%3D Child J, Andrews JM, Wise R. Pharmacokinetics and tissue penetration of the new fluoroquinolone grepafloxacin. Antimicrob Agents Chemother 1995; 39: 513–5
19. 19. PJ Cook JM Andrews R Wise 1995 Concentrations of OPC-17116, a new fluoroquinolone antibacterial, in serum and lung compartments J Antimicrob Chemother 35 317 26 7759395 10.1093/jac/35.2.317 1:CAS:528:DyaK2MXktV2qsL4%3D Cook PJ, Andrews JM, Wise R, et al. Concentrations of OPC-17116, a new fluoroquinolone antibacterial, in serum and lung compartments. J Antimicrob Chemother 1995; 35: 317–26